---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-055334"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2025-06-18T23:59:59+00:00"
generated_at: "2026-05-19T02:55:01.302086+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Relmada appoints Dr. Raj S. Pruthi as CMO-Urology for NDV-01 NMIBC program

## Summary
- Dr. Raj S. Pruthi appointed Chief Medical Officer-Urology effective June 17, 2025.
- He will lead development of NDV-01, a gemcitabine/docetaxel sustained release formulation for NMIBC.
- Company presented positive Phase 2 data at AUA 2025; Phase 3 trial expected to begin H1 2026.
- Dr. Pruthi brings over 25 years experience in urologic oncology, including roles at enGene and J&J.

## SEC filing metadata
- accession: 0001213900-25-055334
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2025-06-18T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390025055334/0001213900-25-055334-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390025055334/ea0246111-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-055334
- JSON: https://secwatch.observer/filing/0001213900-25-055334.json
- Plain text: https://secwatch.observer/filing/0001213900-25-055334.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.